• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Assessing clinical response and defining minimal disease activity in plaque psoriasis with the Physician Global Assessment and body surface area (PGA × BSA) composite tool: An analysis of apremilast phase 3 ESTEEM data.

作者信息

Gottlieb Alice B, Merola Joseph F, Chen Rongdean, Levi Eugenia, Duffin Kristina Callis

机构信息

New York Medical College, Valhalla, New York.

Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.

出版信息

J Am Acad Dermatol. 2017 Dec;77(6):1178-1180. doi: 10.1016/j.jaad.2017.06.162.

DOI:10.1016/j.jaad.2017.06.162
PMID:29132853
Abstract
摘要

相似文献

1
Assessing clinical response and defining minimal disease activity in plaque psoriasis with the Physician Global Assessment and body surface area (PGA × BSA) composite tool: An analysis of apremilast phase 3 ESTEEM data.使用医师整体评估和体表面积（PGA×BSA）综合工具评估斑块状银屑病的临床反应并定义最小疾病活动度：阿普斯特3期ESTEEM数据的分析
J Am Acad Dermatol. 2017 Dec;77(6):1178-1180. doi: 10.1016/j.jaad.2017.06.162.
2
Evaluation of the Physician Global Assessment and Body Surface Area Composite Tool for Assessing Psoriasis Response to Apremilast Therapy: Results from ESTEEM 1 and ESTEEM 2.评估医师整体评估和体表面积综合工具用于评估银屑病对阿普米拉斯治疗的反应：来自ESTEEM 1和ESTEEM 2的结果。
J Drugs Dermatol. 2017 Feb 1;16(2):147-153.
3
Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with difficult-to-treat nail and scalp psoriasis: Results of 2 phase III randomized, controlled trials (ESTEEM 1 and ESTEEM 2).阿普米司特，一种口服磷酸二酯酶 4 抑制剂，用于治疗难治性指甲和头皮银屑病患者：两项 III 期随机对照试验（ESTEEM 1 和 ESTEEM 2）的结果。
J Am Acad Dermatol. 2016 Jan;74(1):134-42. doi: 10.1016/j.jaad.2015.09.001.
4
Real-World Clinical Experience With Apremilast in a Large US Retrospective Cohort Study of Patients With Moderate to Severe Plaque Psoriasis.在美国一项针对中度至重度斑块状银屑病患者的大型回顾性队列研究中使用阿普米司特的真实世界临床经验。
J Drugs Dermatol. 2017 Dec 1;16(12):1240-1245.
5
Apremilast, an oral phosphodiesterase-4 inhibitor, in the treatment of palmoplantar psoriasis: Results of a pooled analysis from phase II PSOR-005 and phase III Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis (ESTEEM) clinical trials in patients with moderate to severe psoriasis.阿普米司特，一种口服磷酸二酯酶-4 抑制剂，治疗掌跖银屑病：来自 PSOR-005 Ⅱ期和 Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis（ESTEEM）Ⅲ期临床试验的汇总分析结果，该试验入组了中重度银屑病患者。
J Am Acad Dermatol. 2016 Jul;75(1):99-105. doi: 10.1016/j.jaad.2016.02.1164. Epub 2016 Mar 24.
6
Comparative efficacy and incremental cost per responder of methotrexate versus apremilast for methotrexate-naïve patients with psoriasis.甲氨蝶呤初治银屑病患者中，甲氨蝶呤与阿普米司特的疗效比较和应答者增量成本。
J Am Acad Dermatol. 2016 Oct;75(4):740-746. doi: 10.1016/j.jaad.2016.05.040. Epub 2016 Jul 28.
7
Efficacy, tolerability, and pharmacodynamics of apremilast in recalcitrant plaque psoriasis: a phase II open-label study.阿普司特治疗顽固性斑块状银屑病的疗效、耐受性及药效学：一项II期开放标签研究。
J Drugs Dermatol. 2013 Aug;12(8):888-97.
8
The reliability of three psoriasis assessment tools: Psoriasis area and severity index, body surface area and physician global assessment.三种银屑病评估工具的可靠性：银屑病面积和严重程度指数、体表面积和医师整体评估。
Adv Clin Exp Med. 2017 Aug;26(5):851-856. doi: 10.17219/acem/69804.
9
Improvement of Nail and Scalp Psoriasis Using Apremilast in Patients With Chronic Psoriasis: Phase 2b and 3, 52-Week Randomized, Placebo-Controlled Trial Results.使用阿普米拉斯治疗慢性银屑病患者指甲和头皮银屑病的疗效：2b期和3期、52周随机、安慰剂对照试验结果
J Drugs Dermatol. 2016 Mar;15(3):272-6.
10
Effects of Apremilast on Pruritus and Skin Discomfort/Pain Correlate With Improvements in Quality of Life in Patients With Moderate to Severe Plaque Psoriasis.阿普米拉斯对中度至重度斑块状银屑病患者瘙痒及皮肤不适/疼痛的影响与生活质量改善相关。
Acta Derm Venereol. 2016 May;96(4):514-20. doi: 10.2340/00015555-2360.

引用本文的文献

1
Development of Psoriasis Assessment Tools Among Patients in the CorEvitas Psoriasis Registry.科瑞维塔斯银屑病登记处患者中银屑病评估工具的开发
J Psoriasis Psoriatic Arthritis. 2023 Apr;8(2):74-82. doi: 10.1177/24755303231155118. Epub 2023 Mar 21.
2
Genetic polymorphisms to identify patients with an optimal response to tildrakizumab in psoriasis patients from real-life clinical practice.鉴定在真实临床实践中接受度伐鲁单抗治疗的银屑病患者中对其有最佳应答的遗传多态性。
Exp Dermatol. 2024 Aug;33(8):e15152. doi: 10.1111/exd.15152.
3
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
系统性药物治疗慢性斑块状银屑病：网络荟萃分析。
Cochrane Database Syst Rev. 2023 Jul 12;7(7):CD011535. doi: 10.1002/14651858.CD011535.pub6.
4
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.系统性药理学治疗慢性斑块型银屑病：网络荟萃分析。
Cochrane Database Syst Rev. 2022 May 23;5(5):CD011535. doi: 10.1002/14651858.CD011535.pub5.
5
Deucravacitinib in Moderate to Severe Psoriasis: Clinical and Quality-of-Life Outcomes in a Phase 2 Trial.德卡伐替尼治疗中度至重度银屑病：一项2期试验的临床和生活质量结果
Dermatol Ther (Heidelb). 2022 Feb;12(2):495-510. doi: 10.1007/s13555-021-00649-y. Epub 2022 Jan 13.
6
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.系统性药理学治疗慢性斑块状银屑病：网络荟萃分析。
Cochrane Database Syst Rev. 2021 Apr 19;4(4):CD011535. doi: 10.1002/14651858.CD011535.pub4.
7
Product of Investigator Global Assessment and Body Surface Area (IGAxBSA): A practice-friendly alternative to the Eczema Area and Severity Index to assess atopic dermatitis severity in children.研究者全球评估与体表面积乘积（IGAxBSA）：一种简便实用的替代湿疹面积和严重程度指数的方法，用于评估儿童特应性皮炎的严重程度。
J Am Acad Dermatol. 2020 May;82(5):1187-1194. doi: 10.1016/j.jaad.2020.01.023. Epub 2020 Jan 21.
8
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.慢性斑块状银屑病的全身药理学治疗：一项网状Meta分析。
Cochrane Database Syst Rev. 2020 Jan 9;1(1):CD011535. doi: 10.1002/14651858.CD011535.pub3.
9
Diagnostic and therapeutic guidelines for plaque psoriasis - Brazilian Society of Dermatology.斑块状银屑病的诊断和治疗指南 - 巴西皮肤病学会
An Bras Dermatol. 2019 Apr;94(2 Suppl 1):76-107. doi: 10.1590/abd1806-4841.2019940211. Epub 2019 Jun 30.
10
Exploration of the Product of the 5-Point Investigator's Global Assessment and Body Surface Area (IGA × BSA) as a Practical Minimal Disease Activity Goal in Patients with Moderate-to-Severe Psoriasis.探讨 5 分制研究者全球评估与体表面积（IGA×BSA）乘积作为中重度银屑病患者实用的最小疾病活动度目标。
Dermatology. 2019;235(4):348-354. doi: 10.1159/000499925. Epub 2019 May 29.